A postulated mechanism of beta-sympathomimetic induction of rib and limb anomalies in rat fetuses.
Treatment of gravid rats (days 6-15 of gestation) with the beta-sympathomimetic doxaminol resulted in wavy ribs and bent limbs in the offspring. The fetuses also exhibited defective mineralization. These anomalies were produced by pharmacologically effective doses of the drug. Prior treatment with the beta-receptor blocker carazolol prevented their formation, so that the beta-sympathomimetic action of doxaminol is evidently a causative factor. Various hypotensive agents whose activity is not mediated by beta-receptors failed to produce abnormalities. This eliminates the possibility of a non-specific etiology such as diminished placental perfusion. The cyclooxygenase inhibitor indomethacin lowered the incidence of wavy ribs. Furosemide, a loop diuretic that stimulates renal prostaglandin synthesis, increased the incidence of abnormalities when combined with doxaminol. The nature of the anomalies found suggests that 1) fetal compression by the myometrium and 2) defective mineralization are prerequisites for their development. The first condition could be produced via the complex mechanism of beta-sympathomimetic-induced stimulation of prostaglandin synthesis. Defective mineralization can result directly from cAMP-mediated activation of osteoclasts and possibly be further promoted by beta-sympathomimetic-mediated prostaglandin action on the osteoclast. The pathological findings in the fetal rat skeleton cannot be correlated with corresponding findings in human neonates whose mothers were subjected to prolonged therapeutic uterine relaxation with beta 2-sympathomimetics, for example. Since the anomalies in the rat disappear spontaneously in the post-natal period, their clinical relevance appears to be slight.
Sterz
H
H
Sponer
G
G
Neubert
P
P
Hebold
G
G
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000318:Adrenergic beta-Agonists / Q000633:toxicity*; D000818:Animals; D003990:Dibenzoxepins / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D017880:Limb Deformities, Congenital; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D051381:Rats; D012272:Ribs / Q000002:abnormalities*; D014665:Vasodilator Agents / Q000633:toxicity
D000318:Adrenergic beta-Agonists; D003990:Dibenzoxepins; D014665:Vasodilator Agents; C034187:doxaminol; D005665:Furosemide; D007213:Indomethacin